MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, RIGL had -$4,873K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$4,873K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net income
27,900 71,059
Stock-based compensation expense
3,363 6,600
Depreciation and amortization
603 1,211
Release of cost share liability
0 39,981
Net amortization of discount on short-term investments and term loans
467 440
Accounts receivable, net
6,018 -1,708
Inventories
-188 6,954
Prepaid and other current and non-current assets
1,872 6,589
Right-of-use assets
128 -932
Accounts payable
-3,444 3,951
Accrued compensation
2,168 -2,242
Accrued research and development
695 48
Revenue reserves and refund liability
518 3,062
Other accrued liabilities
350 -1,803
Lease liabilities
-81 946
Net cash provided by operating activities
24,031 29,644
Maturities of short-term investments
20,730 26,850
Purchases of short-term investments
53,893 60,678
Capital expenditures
12 -
Net cash (used in) provided by investing activities
-33,175 -33,828
Net proceeds from issuance of common stock from equity plans
4,271 902
Net cash provided by (used in) financing activities
4,271 902
Net (decrease) increase in cash, cash equivalents and restricted cash
-4,873 -3,282
Cash and cash equivalents at beginning of period
56,746 -
Cash and cash equivalents at end of period
48,591 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

RIGEL PHARMACEUTICALS INC (RIGL)

RIGEL PHARMACEUTICALS INC (RIGL)